Northwest Biotherapeutics (NWBO) Operating Leases (2019 - 2026)

Northwest Biotherapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 4.03% year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a 4.03% decrease from a year earlier, with the FY2025 full-year figure at $4.4 million, down 0.61% from the prior year.
• Operating Leases retreated to $4.3 million in Q1 2026 per NWBO's latest filing, from $4.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $5.0 million in Q1 2022 and bottomed at $4.1 million in Q3 2022.
• The 5-year median for Operating Leases is $4.4 million (2025), against an average of $4.5 million.
• Across the five-year window, Operating Leases slipped 21.91% in 2022 and climbed 16.79% in 2024, its largest moves.
• Year by year, Operating Leases stood at $4.4 million in 2022, then advanced by 1.92% to $4.5 million in 2023, then declined by 0.36% to $4.4 million in 2024, then dropped by 0.61% to $4.4 million in 2025, then declined by 2.72% to $4.3 million in 2026.
• Per Business Quant, the three latest NWBO Operating Leases figures stand at $4.3 million (Q1 2026), $4.4 million (Q4 2025), and $4.4 million (Q3 2025).